What were the findings of the RE-LY trial regarding dabigatran versus warfarin in patients with atrial fibrillation?
The RE-LY trial, published in 2009, found that dabigatran was superior to warfarin in terms of efficacy and safety in patients with atrial fibrillation. Specifically, dabigatran was associated with a lower risk of stroke and systemic embolism, and a lower risk of major bleeding compared to warfarin. Other subgroup analyses of the RE-LY trial also found that dabigatran was associated with a lower risk of mortality and myocardial ischemic events compared to warfarin. Furthermore, dabigatran was associated with a lower risk of bleeding compared to warfarin in both older and younger patients. 